Zoetis (ZTS) Other Accumulated Expenses (2013 - 2026)
Zoetis' (ZTS) quarterly Other Accumulated Expenses came in at $121.0 million in Q1 2026, down 84.33% year-on-year from $772.0 million in Q1 2025, and down 85.61% on a QoQ basis from $841.0 million in Q4 2025.
Zoetis (ZTS) Other Accumulated Expenses (2013 - 2026) Analysis & Trends
Zoetis (ZTS) has 14 years of Other Accumulated Expenses data on file, last reported at $121.0 million in Q1 2026.
- On a quarterly basis, Other Accumulated Expenses fell 84.33% year-over-year to $121.0 million in Q1 2026; TTM through Mar 2026 was $121.0 million, a 84.33% decrease from a year earlier, with the FY2025 full-year figure at $841.0 million, up 572.8% from the prior year.
- Other Accumulated Expenses for Q1 2026 stood at $121.0 million, down from $841.0 million in the prior quarter.
- Over the last five years, Other Accumulated Expenses for ZTS reached as high as $841.0 million in Q4 2025 and fell as low as $89.0 million in Q1 2024.
- Historically, Other Accumulated Expenses has averaged $399.8 million across 5 years, with a median of $125.0 million in 2024.
- Across the five-year window, Other Accumulated Expenses tumbled 87.3% in 2024 and soared 767.42% in 2025, its largest moves.
- Year by year, Other Accumulated Expenses stood at $97.0 million in 2022, then gained by 5.15% to $102.0 million in 2023, then increased by 22.55% to $125.0 million in 2024, then jumped by 572.8% to $841.0 million in 2025, then tumbled by 85.61% to $121.0 million in 2026.
- Per Business Quant data, the three most recent Other Accumulated Expenses figures were $121.0 million in Q1 2026, $841.0 million in Q4 2025, and $99.0 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 89.15 Bn | 87.28 Bn | - |
| 2 | Teva Pharmaceutical Industries | 35.85 Bn | 32.11 Bn | 1.97 Bn |
| 3 | Zoetis | 32.52 Bn | 30.58 Bn | 1.62 Bn |
| 4 | Takeda Pharmaceutical | 27.53 Bn | 23.47 Bn | 4.39 Bn |
| 5 | United Therapeutics | 23.21 Bn | 21.06 Bn | 648.10 Mn |
| 6 | RedHill Biopharma | 21.76 Bn | 21.76 Bn | - |
| 7 | Viatris | 20.30 Bn | 18.50 Bn | 1.16 Bn |
| 8 | Neurocrine Biosciences | 17.74 Bn | 16.42 Bn | 800.70 Mn |
| 9 | Elanco Animal Health | 12.59 Bn | 12.16 Bn | 785.00 Mn |
| 10 | Vireo Growth | 10.52 Bn | 10.37 Bn | 59.30 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 121.00 Mn |
| Dec 31, 2025 | 841.00 Mn |
| Sep 30, 2025 | 99.00 Mn |
| Jun 30, 2025 | 770.00 Mn |
| Mar 31, 2025 | 772.00 Mn |
| Dec 31, 2024 | 125.00 Mn |
| Sep 30, 2024 | 115.00 Mn |
| Jun 30, 2024 | 704.00 Mn |
| Mar 31, 2024 | 89.00 Mn |
| Dec 31, 2023 | 102.00 Mn |
| Sep 30, 2023 | 97.00 Mn |
| Jun 30, 2023 | 689.00 Mn |
| Mar 31, 2023 | 701.00 Mn |
| Dec 31, 2022 | 97.00 Mn |
| Sep 30, 2022 | 679.00 Mn |
| Jun 30, 2022 | 696.00 Mn |
| Mar 31, 2022 | 99.00 Mn |
| Dec 31, 2021 | 67.00 Mn |
| Sep 30, 2021 | 618.00 Mn |
| Jun 30, 2021 | 646.00 Mn |